Sign inJoin waitlistJoin the waitlist

Mark Genovese

M.D. Professor, Emeritus · Stanford Health Care

Credentials: · · ·

History

Stanford University Immunology and Rheumatology Fellowship (1998) CA
1996–1998
Stanford University
1992–1993
Johns Hopkins Univ Sch of Med
1988–1992
University of Notre Dame
1984–1988

Research

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
New England Journal of Medicine · 2000 · 1,429 citations
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial…
Arthritis & Rheumatism · 2006 · 1,313 citations
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
New England Journal of Medicine · 2005 · First of 14 authors · Corresponding · 964 citations

RF
Roy Fleischmann
24 papers
AK
Alan Kivitz
23 papers
MW
Michael Weinblatt
21 papers
JK
Joel Kremer
19 papers
SC
Stanley Cohen
16 papers
Arthur Kavanaugh
14 papers
MS
Michael Schiff
13 papers
EH
Elizabeth Hsia
12 papers
Larry Moreland
11 papers
MG
Maria Greenwald
11 papers
Stuart Goodman
11 papers
Joan Bathon
10 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $102.8K · Stanford University
2004–2008

Clinical trials

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Principal investigator · Completed · Phase 2
AbGenomics B.V Taiwan Branch
2015–2016
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
Principal investigator · Terminated · Phase 2
UCB BIOSCIENCES, Inc.
2011–2013
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
Principal investigator · Withdrawn · Phase 2
Stanford University
2010–2011
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Principal investigator · Terminated · Phase 2
PDL BioPharma, Inc.
2005–2006